Table 1.
Demographic and clinical data for PD and control subjects
| Control | PD | PDE | P values | |
|---|---|---|---|---|
| Study 1 participants (N) | 70 | 76 | 35 | |
| Age, yrs | 61.3 (6.7) | 63.3 (8.4) | 61.1 (8.7) | 0.113 |
| Female/Male (N) | 36/34 | 29/47 | 18/17 | 0.134 |
| Disease duration, yrs | - | 4.9 (5.5) | 0.8 (0.6) | - |
| Hoehn-Yahr Stage, I/II/III | - | 29/33/14 | 19/11/5 | - |
| UPDRS III | - | 21.5 (14.9) | 16.1 (9.7) | - |
| LEDD | - | 608 (466) | 292 (230) | - |
| HDRS | 3.8 (2.5) | 7.0 (4.2) | 7.0 (4.0) | <0.001 |
| MoCA | 26.1 (2.5) | 24.6 (3.6) | 25.3 (2.6) | 0.041 |
| Study 2 participants (N) | 49 | 73 | 35 | |
| Age, yrs | 68.7 (11.6) | 67.7 (10.2) | 64.6 (10.2) | 0.424 |
| Female/Male (N) | 23/26 | 32/41 | 17/18 | 0.736 |
| Disease duration, yrs | - | 5.8 (6.0) | 0.8 (0.7) | - |
| Hoehn-Yahr Stage, I/II/III/IV/V | - | 17/39/8/5/4 | 17/16/2 | - |
| UPDRS III | - | 30.1 (22.9) | 19.8 (13.2) | - |
| LEDD | - | 678 (445) | 413 (239) | - |
| HDRS | 3.2 (3.0) | 5.9 (4.4) | 4.8 (3.7) | <0.001 |
| MoCA | 25.2 (2.4) | 23.8 (4.2) | 24.8 (2.5) | 0.004 |
Date represent means with standard deviations in parentheses unless otherwise indicated. P values represent the difference between control and overall PD groups and controls. PDE (early stage PD) is defined by disease duration <2 yrs. UPDRS III: MDS-Unified Parkinson’s Disease Rating Scale III motor subscore; LEDD: Levodopa equivalent daily dosage; HDRS: Hamilton Depression Rating Scale; MoCA: Montreal Cognitive Assessment.